Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02101788 (A Randomized Phase II/III Study to Assess the Efficacy of Trametinib), which is not on this map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT02101788 phase2 / phase3completednot on this map
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2014 to 2025Enrolled260ConditionsBorderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous AdenocarcinomaArmsLetrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Robert L HollisThe Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-1390-3298
Austin MillerNRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-9739-8462
Heather A LankesNRG Oncology, Operations Center-Philadelphia East, Philadelphia, Pennsylvania.ORCID 0000-0001-8814-5033
Kwong-Kwok WongDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0375-6669
William RodgersNYPQ, Department of Pathology, Weill Medical College of Cornell University, New York, New York.ORCID 0009-0002-1247-3107
Karen CartyCancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-5040-6381
Robert L ColemanDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9343-8754
Kathleen N MooreStephenson Cancer Center at the University of Oklahoma, Oklahoma City, Oklahoma.ORCID 0000-0002-5803-0718
David M O'MalleyOhio State University and the James Cancer Center, Columbus, Ohio.ORCID 0000-0002-2828-0177
John K ChanGynecologic Oncology, Sutter Cancer Research Consortium, San Francisco, California.ORCID 0000-0003-3379-6829
Andrea R HagemannWashington University, Gynecologic Oncology, St. Louis, Missouri.ORCID 0000-0002-3484-0046
Stephanie GaillardSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland.ORCID 0000-0002-2174-3693
Saketh R GuntupalliGynecologic Oncology, University of Colorado School of Medicine, UC Health CU Cancer Center, Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2570-6635
Mitchell I EdelsonAbington Hospital, Gynecologic Oncology, Abington, Pennsylvania.ORCID 0000-0001-6708-7380
Peter G RoseGynecologic Oncology, Case Comprehensive Cancer Center and Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0003-2676-0166
Oliver DorigoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford, California.ORCID 0000-0002-1976-5201
Susana BanerjeeThe Royal Marsden Hospital NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-8840-7934
Ailith EwingMRC Human Genetics Unit & CRUK Scotland Centre, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.ORCID 0000-0002-2272-1277
Michael ChurchmanThe Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0003-1958-7692
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4242-1762
C Simon HerringtonThe Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-9177-8165
Charlie GourleyThe Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-2377-7221
David M GershensonDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9712-2140
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4M
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3M
NCI National Clinical Trials Network - Lead Academic Participating SiteUG1CA233324 · NCI · UNIVERSITY OF COLORADO DENVER · PI ANTHONY D ELIAS · 2019 to 2026
$5.2M
Cancer Research UK (CRUK) CTRQQR-2021/100006Cancer Research UK (CRUK) RCCCDF-Nov24/100001NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA233324NCI NIH HHS UG1 CA233339NRG Oncology (NRG Oncology Foundation, Inc.) U10CA180822NRG Oncology (NRG Oncology Foundation, Inc.) U10CA180868NRG Oncology (NRG Oncology Foundation, Inc.) U24CA196067Target Ovarian Cancer (TOC) CG-19
6 · The paper itself
Abstract
purposeLow-grade serous ovarian carcinoma (LGSOC) is a distinct form of ovarian cancer characterized by younger patient age and relative chemoresistance. The GOG281/LOGS trial (NCT02101788) investigated the efficacy of the MEK inhibitor trametinib compared with physician's choice standard-of-care (SOC) in patients with LGSOC with persistent/recurrent disease. The study demonstrated significantly improved progression-free survival (PFS) in the trametinib-treated arm. EXPERIMENTAL
designTwo hundred and sixty patients with recurrent/persistent LGSOC were enrolled and randomly assigned in GOG281. We performed molecular analysis of 170 patients with available tumor specimens, comprising whole-exome sequencing and phospho-ERK (pERK) IHC, to identify biomarkers of clinical benefit from trametinib. The demographics of the translational cohort (n = 170) were comparable with those of the total trial cohort.
resultsHigh tumor pERK expression (greater than the median histoscore of 140) was associated with significantly prolonged PFS with trametinib treatment versus SOC (median 20.1 vs. 5.6 months, log-rank P < 0.0001; test for interaction P = 0.023). Tumors harboring canonical RAS-RAF-MAPK mutations (KRAS/BRAF/NRAS: 44/134, 32.8% of cases) had a higher response rate to trametinib (50.0% vs. 8.3%; Barnard's P = 0.0004; test for interaction P = 0.054), but KRAS/BRAF/NRAS status was not predictive of prolonged PFS (test for interaction P = 0.719). KRAS amplification (n = 5 without KRAS/NRAS/BRAF mutation) and mutation of MAPK-associated genes (n = 25 without KRAS/NRAS/BRAF mutation or KRAS copy number gain) expanded the number of cases with identifiable MAPK defects to 55.2%, but consideration of these events did not improve the discrimination of trametinib responders. Chr1p loss (49% of cases) was associated with lower pERK expression (P = 0.021).
conclusionsThis exploratory analysis suggests that pERK expression and mutation of KRAS/BRAF/NRAS are candidate biomarkers of improved PFS and response to trametinib, respectively.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. · full record | OpenQuestion